Summary.-Part I of this report appeared in the previous issue (Br. J. Cancer (1976) 
Requests for reprints to R. Peto, Radcliffe Infirmary, Oxford, England; or to M. C. Pike, University of Southern California School of Medicine, Los Angeles, California 90033, U.S.A. Reprints of both parts will be sent to those who request reprints of either part. Bulk orders for teaching purposes cost £5 or $10 per 10; please inform us if any details are unclear, misleading or wrong. differs between groups of patients who differ with respect to an " explanatory variable ", such as age or disease stage, recorded at the time of randomization (using life tables and logrank tests to compare these groups with each other). (iv) Retrospective stratification, based on the findings in (iii), followed by recalculation of the P-value comparing treatment groups making proper allowance for which of these strata each patient is in.
17.-Definition of the " trial time " for each patient " Time " is measured for each patient from that particular patient's date of randomization. After deciding to analyse the results a stopping date, perhaps the end of a particular month, is chosen and for each patient in the trial it is determined whether he was alive or dead on that date and, if dead, the date on which he died. (Deaths occurring shortly after the chosen stopping date are ignored in this analysis, even if they are known of when analysis occurs, since otherwise the risk of death would be slightly exaggerated.) If the collaborating centres have enough advance warning of the stopping date, they can arrange appointments for all their surviving patients for a few days after this date, and the data collection can then be completed within a matter of weeks of the stopping date. It is certainly not sufficient to rely on busy collaborating physicians to notify a trial centre whenever deaths occur; delays of several months would then be commonplace, and some deaths might be completely missed. Curiously, recall (in response to telephone enquiries) of how long ago deaths occurred or patients were last seen is very unreliable, many events being remembered as being considerably more recent than they actually were. Exact dates when patients died or were last seen must, unfortunately, be determined. Unfortunately, this simple and sensible graph of " proportion alive " against " time since randomization " can be fully plotted only if all the patients are already dead before analysis of the data is undertaken. For example, if some of the patients are still alive with trial times less than one year (because they were randomized only a few months ago), we cannot yet know if they will eventually survive a full year from randomization or not, and so there is no simple and obvious estimate of the proportion of all patients who will be alive at one year.
However, to survive a whole year, a patient has to survive each of the 365 days comprising it, and this apparently trivial observation is the key to efficient estimation of how many will live the full year out. We need first to look at the death rates observed on each individual day, and then to argue that, for example, the way to live 31 days is to live 30 days and then to live one more day.
Translated into the language of probabilities, this means that the probability of living 31 days from randomization is the probability of living 30 days multiplied by the chance of surviving Day 31 after living 30 days: they are multiplied together since this is how one combines such probabilities. It is essential that the previous sentence be clearly understood, for without it the remainder of this section will be obscure. (It is just analogous to the calculation that if 2 coins are tossed in succession, the probability of both being heads is one-quarter, this being the product of the probability that the first coin is heads, which is onehalf, and the probability, after the first coin has come down heads, that the second coin will now do so, which is also one-half.) This simple rule is all that underlies the calculation of " life table " graphs. It follows fairly straightforwardly from it that the chance of living a year from randomization is C1 X C2 X C3 X C4 X ... X C364 X C365 where:
C0 denotes the chance of surviving at least one day from randomization C2 denotes the chance of surviving a second day after you have survived one day from randomization C3 denotes the chance of surviving a third day after you have survived 2 days from randomization 25, 14, 11, 10, 8, 7, 7, 7, 4. estimates The reason for wanting to know how many patients are alive and still being followed up at a particular time from randomization is that this information can be used for a quick (but quite accurate; see statistical note 6) estimate of how much your life table at that time might differ from the value it would have had in a vastly larger, and hence more accurate, study. However, these estimates should not usually be used for the calculation of P-values; for this, the logrank test, which is described below, is preferable since it takes into account the overall structure of the 2 curves being compared, not just their values at one time.
(Over periods as long as 5 or 10 years from entry, an appreciable proportion of a group of old patients would be expected to die from other causes, and so adjusted" 5-or 10-vear percentage survivals are sometimes cited. These are simply the life-table estimates of the proportion of the diseased patients still alive at 5 or 10 vears a-s a percentage of the proportion that would have been alive had only the national age-and sex-specific death rates prevailed.)
19.-The Logrank test This involves counting the number of deaths observed in each group, 0, and comparing it with E, the extent of exposure to risk of death in that group; the method of calculating E is given below.
The basis of the logrank test is so straightforward that it seems surprising that it was first suggested only as recently as 1966 (Mantel, 1966) . Breslow (1975) and all subsequent years. Whatever periods the time from randomization is split into, the most important comparison is that for all periods together. This is the "' logrank test" comparing the overall difference between the whole survival curve for A and that for B. Tables (such as Table IV ) of observed numbers of deaths, 0, and extents of exposure to risk of death, E, for the whole period of observation, give a concise summarv of the trial results.* The ratio O/E for a subgroup is called the relative death rate for that subgroup, because it approximates to the ratio of the daily death rate in that subgroup to the daily death rate among all groups combined. Therefore, the ratio of 2 O/E's from different subgrups can be used to describe the apparent ratio of the corresponding death rates. For example, in Table  IV 20.-Loqrank sinificance levels P-values may be estimated by comparing the sum of (O-E)2/E with an appropriate chi-square distribution.
The approximate statistical significance of differences between observed numbers of deaths, 0, and extents of exposure to risk of death, E, in different groups, can be calculated quite rapidly.
In each group we can calculate (O-E)2/E. The more discrepant the value of 0 in a particular group is from the value of E in that group, the bigger (0-E)2/E in that group will tend to be.
Suppose that we calculate (0-E)2/E in each group and that we then add these up, one term from each group. This is something which we shall want to discuss in many places in this paper. It is therefore convenient to have a brief name for the sum of all the (0-E)2/E values, and we choose to call it X2. Likewise, we shall let the svmbol k denote the * There is obviously some sort of analog between E, the total extent of exposure in a subgroup, and an expected nurmber of deaths in that subgroup, and because of this, E is often referred to as the " expected number of deaths ". Unfortunately, in a group of patients who stay alive longer than average, E may, as in Table IV , exceed the number of patients originally randomized into a group. Since it would seem paradoxical to " expect " more deaths than there are patients, the name " extent of exposure " for E is perhaps preferable. However, both names are now sanctioned by usage in published work and, whichever name is used, the statistical arguments are equally valid. number of groups being compared with each other: in many clinical trial analvses, k 2.
If there are k treatment groups and the prognosis of each group is, in fact, the same, then X2 will usually be roughly equal to (k-l).* If, on the other hand, the prognosis in different groups is really different, the observed numbers, 0, in each group will be svstematicallv different from the corresponding extents of exposure, E, and X2 will tend to be greater than k-1. Large values for X2, therefore, although they could arise by chance, constitute evidence for real differences between the prognoses in the k groups. It is possible to calculate the approximate probability that X2 would, if the prognosis were the same in all k groups, exceed any particular given value-and, of course, the larger the given value the less probable this is. This probability, which we call the significance level " or "P-value ", is estimated by an analogy between the behaviour of X2 if the k treatments were identical and the behaviour of one of the standard distributions of statistics, the chi-square distribution. Actuallv, there are lots of different chi-square distributions, each with a different mean value; we can have a chi-square distribution with mean 1, a chi-square distribution with mean 2, and so on: the mean value of a particular chi-square distribution is called the degrees of freedom" of that chi-square distribution, for reasons which are not essential here. Since, if the prognoses are the same in all k groups, the expected value of X2 is approximatelv (k-i), we shall use the analogy with the chi-square distribution with mean (k-i). This comparison enables us to sav that P, the significance level, is approximatelv the probability that an ordinary chi-square distribution with k-i degrees of freedom shall equal or exceed the observed value of X2. Some of these probabilities are listed in the footnote.t
As an example of the use of these methods, consider the data of Table IV. There are 2 groups, so k = 2 and X2, the sum of (O-E)2/E, is (-11-95)2/51-95 + (11-95)2/38 05 = 6-50.
(N.B. This sum has onlv one term for each group, based on the numbers of deaths: no contributions come from the numbers of survivors.) Comparison of this value with the tabulated behaviour of chi-square with one degree of freedom shows that the observed difference between the 2 treatments is more extreme than would commonly arise bv chance alone: since 5-02 < 6-50 < 6-63, 0-025 > P > 0-01 and since 6-50 nearly equals 6-63, P -0-01. We might, in a publication, sav y The difference is statistically significant (X2 = 6-a0, d.f. 1, P_ 0-01)."
More precise significance levels can be * Although the reasons for this rough equality wiH not be apparent to most non-statisticians, it must unfortunatAy be taken on trust, as its proof is beyond the scope of the present paper; the same is true of the chi-square analogy which follows.
t For any mean value (1, 2, 3, 4 .), the chi-square distribution with that mean has a probability just under 0-05 of exceeding (mean -3 ,'mean). For comparisons of 2, 3, 4, 5 or 6 groups with each other, the minimal value of X2 nec-ssary to generate certain particular P-values is tabulated. (Cox, 1972; Breslow, 1975 This value of X2 is so extreme that it answers the question of chance beyond doubt. However, in less extreme cases, it is preferable to make use of the fact that the groups are ordered, and to test for the existence of a trend in prognosis as we go from the first group to the last group. The trend test seeks not just heterogeneity, but plausible heterogeneity, in which the middle group (or groups) tends to have a more average prognosis than the outer groups, and the outer 11I Table V (the relative death rate in the high-urea group being about 5 times as big as that in the low-urea group), no sane reader will suppose that the differences between the O's and E's arose simply by chance. This particular P-value, therefore, answers an irrelevant question, and need hardly be cited; the most important thing with such data is to characterize the difference, not to test whether it could be due to chance or not. To describe the dependence of prognosis on initial blood urea, we might calculate separately:
(i) the life table for the low-urea patients, (ii) that for the medium-urea patients, (iii) that for the high-urea patients, and plot all three of them on a single graph of " estimated % alive " versus " time since entry to study ".
22.-Use of prognostic factors to refine the treatment comparison If a treatment difference among patients in one stratum is calculated, the sum of all such differences, one per stratum, yields an overall test of whether treatment matters among otherwise similar patients.
In clinical trial analysis, we are interested in whether apparent differences between treatments might be due merely to random allocation of more of the good-prognosis patients to one treatment than to the other treatment. Obviously, anything we know about the major determinants of prognosis can help us to answer this question correctly, and help us to see whether, given the different numbers on each treatment in various prognostic categories, there is any residual relationship of treatment with survival.
In earlier reports of clinical trials, the first step in the analysis was often to examine the percentage of each favourable and unfavourable prognostic feature in each treatment group and, hopefully, to demonstrate that they were not too different. To ensure this, a policy of initial stratification was sometimes adopted, giving alternate patients in each particular prognostic stratum alternate treatments.
With modern methods of analysis of survival data, it does not matter if there is some imbalance of prognostic features between treatments, and stratification on entry is usually unnecessary. The principle underlying these methods is very simple: when the trial is being analysed, find out which of the factors recorded at entry are relevant to prognosis (by the method of the previous section). In the light of this analysis, define a few "prognostic strata ", so that within each stratum the patients all, as far as could have been told at entry to the trial, had a fairly similar prognosis. This is straightforward, if only one of your explanatory variables is strongly related to prognosis. categories with respect to each of the 2 important variables, then your strata might well be the 4, 6 or 9 different combinations of categories of these 2 variables. Stratification with respect to as many as 3 variables is often not necessary, and stratification with respect to more than 3 variables is usually both unnecessary and unwise, unless you have thousands of patients in your study.
Let us suppose that you have now defined, on the basis of explanatory information recorded at entry into the trial, a few retrospective strata. Within the first of these prognostic strata calculate, as above, the observed numbers of deaths and the extents of exposure to risk of death on each treatment, entirely ignoring all the patients in all the other strata. Within the first stratum, the sum of the observed numbers on the various treatments will necessarily equal the sum of the various extents of exposure. If all the treatments being compared are equivalent, then for any one treatment group in this first stratum, the observed number and extent of exposure will differ from each other onlv by random fluctuation. If one treatment is better than the other(s), however, then for that treatment in this stratum, the observed number of deaths is likely to be less than the extent of exposure, although since we have only looked at a fraction of all the patients in the trial so far, this difference is unlikely to be significant. However, we next repeat this analysis for the patients in the second prognostic stratum, and then for the third prognostic stratum, and so on. For a particular treatment, we now have an observed number and an extent of exposure in every stratum, which differ from each other only randomly, unless treatment matters. These may be added, to obtain a grand observed number, 0, and a grand extent of exposure, E, for that treatment. Even if there is no very significant treatment effect within any single stratum, differences in the same direction in several strata can reinforce each other so that the grand O's and E's in certain treatment groups eventually differ from each other significantly, if some treatments really are better than others.
Comparison of these grand observed numbers and extents of exposure (by calculating X2, as previously, and comparing it with the standard chi-square distribution with mean one less than the number of treatments) is not biased in any way by chance correlations between particular prognostic strata and treatment, and statistical tests for significant differences between the grand O's and E's are therefore the best way to assess real treatment benefits. In the MRC myeloma trial, inspection of Table V led us to define 3 prognostic strata (low, medium, and high urea) and after this stratification we eventually found that there was no significant effect of treatment among patients with any given level of urea.
Similar techniques can also, of course, be used to examine the relevance of one factor to prognosis, with other factors being constant. A computer programme capable of doing all such analyses and of plotting or printing life-tables is available on request (see p. 20), and a worked example of the use of explanatory information is given in Appendix 3. An instructive and interesting example of the use of these methods on real data is provided by the report of the Medical Research Council's fourth and fifth therapeutic trials in acute myeloid leukaemia (MRC, 1974 (10) Failure to check really carefully that, on your selected stopping date, all the patients you think are alive really are alive is unwise; many trial organizers underestimate the time it takes for news of death to reach them.
(11) A " one-sided " or " one-tailed" P-value may be cited in a clinical trial report; if so, you should usually double it to get the sort of ordinary P-value which you are used to, and which would emerge from the methods given in this paper. If, in a trial, Group A fares better than Group B, then the probability of A doing at least this much better than B just by chance is the one-sided P-value, while the probability of the difference between A and B being at least this big in one direction or the other (A better or B better) just by chance is the ordinary P-value. (For emphasis, the ordinary P-value is occasionally referred to as the two-sided or two-tailed P-value.) Splitting the time after follow-up into about 3 different periods, and comparing the logrank 0 with E in each period separately, as well as in all 3 added together, is a useful safeguard against misinterpreting situations such as those illustrated in Fig. 6 , where one treatment is only better than another in certain periods. Fig. 6(i) year. Fig. 6 (ii) is a situation where A would be better than B in the first and second years, with no treatment comparison possible in the third year, since there are almost no B survivors to compare with the A survivors. Fig. 6 (iii) depicts a situation which is often worried about, and occasionally encountered, where the treatment which is initially better is actually worse in the long run. The logrank test for data such as those in Fig. 6 (iii) would show that the deathrate among A survivors was better in the first year, worse in the second year, and worse in the third year. In Figs. 6(i) and (ii) the overall logrank test would necessarily show A to be better than B overall, but in Fig. 6 (iii) any result could emerge from the overall logrank test (A better overall, B better overall, or no difference overall). Suppose that an intensive treatment, which might well kill a substantial number of patients early in the trial, is to be compared with a gentler treatment, which is probably not as fatal in the short run but which may be less curative in the long run, producing the pattern illustrated in Fig. 6(iii) . Here, it would be sensible to subdivide time from randomization into an initial period (during which most of the deaths from the intensive treatment would be expected), and a later period, and to accumulate (O-E) for each treatment in the initial period only and (O-E) for each treatment in the later period only, examining these separately. The split between " early " and " late " should be chosen either soon after the intensive treatment becomes less intense, or from consideration of the overall survival curve for all patients together to find when the overall death rate changes. The split should not, of course, be chosen after examination of the 2 separate survival curves for the 2 treatments, for it is too easy to find a time when one treatment has a temporary advantage over the other. Subdividing time in this way is also good policy when the nature of the disease changes as time goes by, e.g. from initial crisis to remission maintenance, as the determinants or correlates of mortality in one period may differ from those in the other. Again, the overall survival curve could be used as an unbiased guide on where to split time to separate an early period of rapid death from a later period.
26.-Arranging the manner in which data will be collected A controlled clinical trial is a substantial research undertaking, and sufficient time and money must be set aside to ensure that the records are always complete and up-to-date.
(1) Make sure that the (extensive) initial data from each patient are collected centrally and checked for completeness immediately the patient is entered, so that missing, obscure or unreadable items can be corrected quickly. Retrospective efforts to supply missing data or check implausible items can be very difficult, and can seriously delay the analysis of the trial. If some data are missing, however, it is (unfortunately!) worth making considerable efforts to collect them, if there is any possibility of doing so, as missing data make the statistical analysis much more difficult, and may make the trial report less easy for other workers to interpret without serious doubts about certain of its conclusions.
(2) If something is assessed by a number, record that number exactly, even though the margin of error may be very wide, and not some rounded or grouped version of it. (E.g. it is better to record haemoglobin exactly than to use it to categorize patients as anaemic/ not anaemic, and it is better to record cigarette consumption exactly than to divide patients into ranges such as 1-4, 5-14, 15-25, etc.) If the effect of a presenting feature on the difference between 2 treatments is likely only to affect one (or a few) causes of death, we may choose to look separately at those causes of death which are considered relevant. The previous methods of analysis carry over exactly to this situation, the numbers at risk on each day being just as before, although the extent of exposure to risk of death from a relevant cause on a particular day is related, not to the total number of deaths on that day, but to the total number of relevant deaths on that day.
Likewise, in calculating the life table, we calculate for each day the proportion who do not die of one of the relevant causes, and then combine these proportions, as in Section 18, to obtain the life table description of mortality from relevant causes only. (This is equivalent to treating deaths from other causes as if they were losses to follow-up, assuming that the different causes of death being studied are independent. Unfortunately, this assumption cannot be tested statistically, but must instead be judged reasonable or not on biological grounds.) For example, in the current MRC polycythaemia trial, which may last for 10 years, we may exclude from certain analyses deaths from causes that are unlikely to be related to polycythaemia or its treatment.
Actually, we shall calculate separately the observed numbers of relevant deaths and the extents of exposure to risk of relevant death by treatment group, and the observed number of non-relevant deaths and the extents of exposure to risk of non-relevant death in each treatment group, so that readers can look either at relevant mortality or at total mortality: observed numbers of deaths from relevant and non-relevant causes can be simply added together to give total numbers of deaths, and so can extents of exposure to risk of relevant and nonrelevant death. Separating a few major causes of death, and calculating in each treatment group the observed numbers of deaths from each cause, and extent of exposure to risk of death from each cause, can help the interpretation of data from clinical trials of slowly progressive diseases. Again taking an example from the polycythaemia trial, we may also examine separately (a) the deaths due to onset of acute leukaemia, (b) the deaths due to marrow fibrosis, and (c) other deaths, to see whether active cytotoxic treatment is more leukaemogenic than simple venesection.
28.-Other end points Life tables and logrank methods can find whether, among survivors on a given day, any particular endpoint is more likely in one group than another; this is very useful, but can be misused.
It may be of use to note that these methods of analysis can as easily be applied to the influence of treatment on events other than death: time to first detection of leukaemia in the central nervous system; time to first cardiovascular event (fatal or not) and so on. In many clinical trials studying solid tumours, 2 separate analyses, one of time to local recurrence and one of time to metastatic spread, may be required in addition to a full analysis of survival duration.
Exactly analogous statistical techniques may be used for any such analyses, except that now we are interested in the time from randomization to the first such " event" instead of to death. Consequently, patients contribute no further information to such an analysis once their first " event " has occurred. The only difficulty is to decide how to deal with patients who die without suffering the event of interest.
If the event is such (e.g. neoplastic recurrence) that few patients die without previously suffering it, the most satisfactory course, for reasons which will soon become clear, is undoubtedly to define our interest as being in " recurrence or death not preceded by recurrence". This means that our life tables will estimate the proportions of recurrencefree survivors at different times, and our O's and E's will test which treatment best prolongs disea8e-free survival.
If, however, the event is such that more patients die without suffering it than ever suffer it, study of it might be swamped if we mixed in all the patients who died without it. An example of this will arise in the current MRC trial comparing venesection with venesection plus cytotoxic treatment for polycythaemia: whether or not any significant difference in total mortality emerges, we shall want to know if, compared with simple venesection, the cytotoxic treatment is leukaemogenic. Counting the few patients who develop leukaemia (including leukaemias which are fatal before the analysis is undertaken and leukaemias which are not) in each group is easy. Calculating the extent of exposure to risk of leukaemia is also easy: we simply argue that on a given day after randomization, all patients who are still alive and free of leukaemia would, if cytotoxic treatment were not leukaemogenic, be equally likely to develop leukaemia. 
29.-Remi&ion duration
If time is measured from the date of remission, analogous analyses of remission duration are possible.
Exactly analogous techniques can be used to studv the duration of remission, if the trial time is taken to start at remission and to end at c;relapse or death without relapse" rather than at death. If the randomization is done before the state of remission is achieved, the time at which the phvsician declares that a patient is in remission may depend on the particular treatment regime that the patient will receive in remission, and this could bias the results. It is therefore preferable, if possible, not to randomize until remission has been achieved, and then to study time approached them have mustered; and consequently many different randomized trials of these treatment comparisons may have been undertaken, none of which is sufficiently accurate on its own. An example might be the possible utility of anti-coagulants following myocardial infarction, or the utility of a particular form of immunotherapy for a particular neoplasm. We might hope to find an overall tendency for patients given A to fare slightly better than patients given B, obscured or enhanced in each particular trial by random variation.
The most efficient unbiased way of determining whether this is so is to ignore in each particular trial all patients allocated to treatments other than A or B, and then to calculate, for each separate trial, 0 and E for Treatment A and 0 and E for Treatment B. Finally, we combine the trials by adding all the O's for Treatment A, to get an overall OA, all the E's for Treatment A, to get an overall EA, and similarly we obtain a combined OB and EB: OA + OB wil equal EA + EB, of course. Comparison of OA with EA and OB with EB in the usual way, by computing X2 = (OA-EA)2/EA + (OB-EB)2/EB and using the analogy between X2 and chi-square with one degree of freedom, will lead to a P-value testing whether A and B are statistically significantly different from each other. Calculation of R = (OA/EA)/(OB/EB) will, moreover, yield a useful pooled estimate of the ratio of the death rate on A to that on B.
This method of pooling different trials treats each trial as though it were a retrospective stratum in a single large trial, and of course would be equally applicable if some of the separate trials were themselves actually subdivided, e. (Mathe et al., 1969) . Eight of the 20 patients treated by immunotherapy had received BCG alone, and it appeared that this was as effective as the other immunotherapy regimens of blast cells alone or BCG combined with blast cells. Animal work had shown that in mice BCG can, under certain circumstances, cure grafted isogeneic leukaemias, and it was hoped that this might be the first news of the breakthrough to a real leukaemia cure. However, approximate comparison with contemporary British experience suggested that, although the treated patients had fared fairly well, the controls had fared much worse than was normal, and that this accounted for much of the disparity between the 2 treatment groups. It was therefore decided that the Medical Research Council should organize a clinical trial to assess these claims made for BCG. If BCG has any effect, first remissions in which BCG is given regularly should on average last longer than first remissions in which no treatment is given; and the trial as originally conceived was to compare unmaintained and BCGmaintained first remissions.
The intake to the trial was to consist of children with acute lymphoblastic leukaemia who had undergone a standard 5-month course of intensive cytotoxic therapy from their time of diagnosis. After this course, maintenance therapy with methotrexate was expected to pro-long the first remission, but possibly to make relapses, when they occurred, more refractory than if no maintenance treatment had been given. (Some leukaemic relapses occurring during unmaintained remission can be controlled by drugs, while others are refractory. If the effect of maintenance treatment during remission is chiefly to suppress those relapses which, had they occurred, could have been controlled anyway, then only the refractory relapses will break through. This effect must be allowed for in the comparison of drug maintenance with immunotherapy-only maintenance, before claims that " immunotherapy in remission facilitates the control of subsequent relapses " can be made.) It appeared, therefore, an open question whether a patient in remission should be left alone or given maintenance chemotherapy.
However, some physicians felt unhappy about not including a maintenance methotrexate group in the trial, and the trial as finally agreed, therefore, had 2 " control " groups, a no-treatment group and a methotrexate group. At each centre, 2-way randomization between immunotherapy and control was used, but which regimen to use for all their control patients was chosen by each centre before the trial began. Intake began in January 1969 and continued to August 1970.
An individual trial cannot exist in isolation. It will of necessity last some years, even if intake only lasts one year, and during this time reports from other workers may make the trial irrelevant, and may even make its continuance unethical. This is a major problem, and must be considered very carefully before starting a trial (Pike, 1973) . About one year after the start of this trial, reports from the United States showed that the extent to which first remission was prolonged by maintenance methotrexate was far greater than had been supposed. The physicians from centres which had chosen the no-treatment control now felt that they should no longer put patients into this group. It was therefore decided that all control patients entered from that time onwards should receive maintenance methotrexate as their control treatment. This detracted from the uniformity of the series of patients, but was in the circumstances unavoidable.
One advantage of the fact that 5 months of standard cytotoxic therapy preceded the allocation to different treatment groups in this trial was that all the " difficult " patients (those who had " bad " veins, refused in-patient treatment, were unable to tolerate the intensive therapy, or were not in remission 5 months after first treatment) were eliminated from the trial before randomization. The group available for randomization was therefore more than usually homogeneous: this generally has the effect of increasing the chances of detecting any differences between the treatments. This uniformity was, however, marred to some extent by the dose of L-asparaginase given in the intensive treatment phase being reduced after the first 50 patients, as the original dose level was proving too toxic and too expensive. This could perhaps have been avoided, had the protocol been tried out more extensively on a pilot basis (MRC, 1971b) just to study its toxicity.
Because of the great interest generated by Mathe's group's results, the trial was analysed at several different times. As we have explained, this is in principle a bad practice, but in this case it was inevitable. These analyses were initially limited to the overall comparison of the 3 treatment groups. To our disappointment, it was soon apparent that the effect of BCG was, if positive at all, only slight. However, since our BCG therapy protocol differed from the French in possibly important ways, this finding is of less value than it might otherwise have been.
Ideally, one should use an identical protocol if one wants to test a published claim, but this was not possible, partly due to difficulty in obtaining the Pasteur Institute vaccine used by the French; partly due to unwillingness to scarify large areas of skin, as they had done, rather than use percutaneous inoculation by Heaf gun; and partly because 7 different protocols were used by the French, each on 2, 3 or 4 of the immunotherapy patients. In retrospect, differences between the MRC protocol and the French protocols meant that the negative result eventually found in our trial is not sufficient to demonstrate that their methods were not effective. However, another, still larger, trial (Heyn et al., 1975) based on Mathe's report has also produced a null result.
In the MRO trial, 191 cases presented, 122 went into remission and were randomized as intended at Month 5, and a further 10 were randomized later, during the next few months. When, in 1971, half the patients had relapsed (though few had died), the results among the 122 were reported (MRC, 1971b) . People who have cited this publication have given less prominence to the fact that there was no statistically significant difference between the first remission durations of the group given BOG and those of the untreated control group, than to the fact that the observed median remission duration, an unreliable statistic, was 27 weeks on BCG and 17 weeks on untreated control. However, partly because this difference diminished as more data accumulated, the remission durations have never been properly reported since. The trial was not a critical test of immunotherapy, because prophylactic treatment of the central nervous system was so inadequate that meningeal relapses prematurely terminated many of the remissions, but since on 1 January 1976 only 3/55 children given immunotherapy were still in first remission (compared with 2/20 given no maintenance and 8/57 given methotrexate) BCG given in this way appears to be of little value (Table VI) .
In Table VI , the fourth line confirms that there is little difference between BCG and untreated control, since the relative relapse rates are so similar (1.25 and 1.32).
If the data for relapses in the BCG and untreated control groups are pooled, the combined relative relapse rate is 1-27: (52 + 18)/(41.58 + 13.61). The relative relapse rate on methotrexate is, by comparison, only 0-77, confirming that maintenance methotrexate really did pro- 94-00 and total extents of exposure to risk of death within WBC strata * Whits blood count at presentation, in units of 10 9/1. Among people in full remission, the original WBC is still a good indicator of how long the remission might last, and among people diagnosed years ago, the original WBC is a useful predictor of future risks of death. and apart from this, the main scientific interest of the trial has, therefore, been the relationship between certain biochemical measurements made on the patients at admission and the survival times (MRC, 1973) .
It was known that a high blood urea indicated renal failure, and was the major determinant of prognosis, but the statistical techniques discussed above enabled us to investigate a whole range of possible explanatory factors. We found that the apparent adverse effects of hypercalcaemia, osteolytic lesions, and the presence of Bence Jones protein in the urine, were wholly explained by their associations with uraemia. The degree of initial anaemia was strongly correlated with prognosis, and as expected, this correlation was by no means completely accounted for by the strong association between uraemia and anaemia. However, one entirely unsuspected factorthe serum albumin-was found to be of substantial prognostic significance, independently of the urea level (Table VII) .
This table is based on 258 of the total of 276 patients entered (18 patients with unusual paraprotein types were excluded from this analysis). The difference between the relative death rates of 1.3 and 0 4 for the low and high albumin patients with no evidence of renal failure, represents a difference between about 18 months and 5 years in median survival time, and is thus of considerable medical significance. The reason for this difference remains obscure. It has been suggested that it might be that the more dangerous myeloma cell populations actually catabolise albumin much more rapidly, but this suggestion has not been properly investigated. Likewise, the reason for the relevance of anaemia to prognosis requires investigation, to see whether the relevant anaemia is chiefly of renal origin or due to bone marrow failure.
In the second MRC myelomatosis trial, daily low-dose cyclophosphamide was compared with intermittent high In the second trial, we again found a statistically significant relationship between albumin and prognosis, but it was a weaker relationship than had been observed in the first trial. This slight disappointment should have been anticipated; moderately strong relationships are often more extreme in the studies where they were first discovered to be interesting than in subsequent studies. This is because a relationship which is in expectation only moderate may, in various different studies, appear weaker than it should or stronger than it should, and it is the latter studies which generate interest. (For the same reason, promising new treatments should not be expected to live up to their early promise.)
We now have extensive initial data, and various numbers of years of follow-up, on a total of over 600 myeloma patients, all treated fairly equivalently. Some of the associations with prognosis (particularly that of anaemia) are proving easier to investigate in this larger series than in the first trial series alone. As far as prognostic correlates and their interpretation are concerned, though, the chief need now is not for still larger numbers, nor for other workers to check our findings on other, probably smaller series, but for new and preferably strikingly different therapeutic strategies to be proposed and tested, and for new factors to be measured in future patients. Since 1975, these have been the aims of the third MRC myelomatosis trial.
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The Statistics Department, University College, London, authorized our reproduction of Table III (I = impaired, or N = normal) at the time of randomization. Some hypothetical data of this type are set out in Table VIII , along with the derivation from them of the trial time. We shall study the relevance of treatment to death from the disease or from causes that might well be correlated with the disease or its treatment, and so we shall not include the death due to a road accident in our analysis. If we wanted to study total mortality, of course, we could easily count this one death and modify the calculated extents of exposure to risk on Day 2240 after randomization accordingly.
Notes on the culatik n of trial times in Table VIII ( with the chi-square distribution with mean one. When we do so, we find that the probability of getting a value of chi-square 3 with 1 degree of freedom as big as or bigger than 1-29 is quite substantial (about 1 in 4), which suggests that the apparent superiority of Treatment A could well have arisen by chance alone.
However, before accepting this conclusion let us first study the relevance of renal function to prognosis. This requires an extra 4 columns of numbers to be added to the right of Table IX , and these are given as Table X .
From Table X (Peto and Pike, 1973; Breslow. 1975-see statistical notes 7 and 8 on p. 38), However, the answers you will obtain by the simiple analogy between X2 and the chispare distribution will give an adequate medical understandingo of the data. As was noted on p. 20, a convenient computer program is available on request which will perform all the analyses described in Appendix 3. examining the relevance to prognosis of an explanatory variable which is split into 3 or more naturally ordered subgroups, should therefore be to calculate both the test for trend (described below) and the X2 test for heterogeneity. However, the P-value ultimately used to help infer whether this explanatory variable is at all related to prognosis should nearly always be based on the test for trend, rather than on that for heterogeneity, even if the statistical significance of the heterogeneity test is slightly more extreme than that of the test for trend.
Computational details. The test for trend involves these steps: (a) Divide the patients into subgroups with respect to the explanatory variable.The choice of the number of subgroups is not usually critical, except that if it is small it is slightly preferable for it to be odd (e.g. 3 or 5) rather than even. It is usually best to aim to have roughly similar numbers (to within a doubling) in each subgroup, although this is not essential, and if medical considerations suggest particular natural groupings, especially of a non-continuous explanatory variable such as disease stage, these should be adopted.
(b) Give each subgroup a number, starting at 1 and working upwards in natural order (e.g. low urea -1, medium urea = 2, high urea = 3).
(c) For each subgroup count 0, the observed number of events, and calculate E, the extent of exposure to risk of such events, according to the methods described in Section 19. Add up the O's to obtain Osum and the E's to obtain Esum, and check that, apart from rounding errors, Osum = Esum. If not, there is an arithmetical error in the derivation of the O's or the E's. (Note that Esum is simply the total number of patients in the whole trial who have suffered an event.) (d) Calculate X2, the test statistic for heterogeneity, as the sum of (O-E)2/E, as in Section 20.
(e) In each subgroup we now have n, the subgroup number, and the logrank 0 and E for that subgroup. Calculate, within each subgroup:
(f) Add up all the A's in the different subgroups to obtain " Asum ". Analogously obtain " Bsum " and " Csum ".
(g) Calculate V where V= Csum-(Bsum x Bsum/Esum) (see statistical note 9 on p. 38). Finally, calculate T, the test statistic for trend, where T = Asum x Asum/V. (If T is negative or exceeds X2 you have made an arithmetical error somewhere: if Osum and Esum are equal after step c, there must be an error in step d, e, f or g.) (h) Obtain a P-value by using an analogy which exists between the behaviour of T if the explanatory variable is in fact irrelevant and the behaviour of one of the standard distributions in statistics, called " chi-square on 1 degree of freedom" (see page 10). This implies that if the explanatory variable is irrelevant (so there is no real trend), then T is zero or positive, and would be expected to be around unity T has an approximately 3 chance of exceeding unity Incidentally, in a test for trend between just 2 groups of patients, so that n = 2, T will necessarily just equal X2.
STATISTICAL NOTES
As in Part I, these are collected together so that they can be completely ignored by the non-statistical reader. The statistical methods recommended in this paper are developed in Kaplan and Meier (1958) , Mantel (1966) , Peto (1972) , Cox (1972) , and Pet4o and Pike (1973) , and are reviewed by Breslow (1975 is referred to tables of chi-square with one degree of freedom. If the continuity correction of 1 is not used, this is necessarily greater than or equal to X2. If more than 2 groups are to be compared a variance/ covariance matrix from each day must be accumulated to give the overall variance/ covariance matrix for the vector of the (O-E)'s in each group, but the principle is similar. Details are given by Peto and Pike (1973) and an example is given in Appendix 3. There is a strong connection between these methods and those of Cox (1972) for comparing 2 groups. Cox uses /3 to denote the log of the ratio of the hazard functions in the 2 treatment groups. He then derives a log-likelihood L(:) and uses the statistic L'(0) to test = 0 noting from likelihood theory that its variance must be approximately -L"(0). In the absence of tied ranks L'(0) and -L"(0) are the logrank (O-E) and its variance V, giving a deeper justification to logrank methods. STATISTICAL NOTE 8. (From p. 33) . In this particular example, where OA= 6 and EA= 10-43 one might use the methods described in the statistical note 7 to compute V -variance of (OA -EA)= 3.39, leading to a chi-square of 4-432/3-39 = 5-79 without a continuity correction, or, if a continuity correction is preferred, (4 43 -)2/3.39 4*56. STATISTICAL NOTE 9.-(From p. 36). The approximation is being made that under the null hypothesis Asum has mean zero (which is exactly true) and variance V (which is not).
The exact variance, Vexact, of Asum may be obtained by noting that, if xi denotes the * Continuity correction. With more than 2 groups, a continuity correction is definitely unwanted, but there is no uniform practice of using or not using a continuity correction when comparing 2 groups by the logrank test, and the reasons why are quite interesting. Two fundamentally different methodls may be available for deriving the P-value from the calculated values of 0 and E in each group, the permutational method (Peto, 1972) or the conditional method (Mantel, 1966) . If there are initially a Group A subjects and b Group B subjects, then both methods calculate a P-value given the times from randomization at which deaths occur and given the durations of follow-up of those who do not die. The permutational P-value, Pperm, is the probability that if a of the a + b patients were selected at random and taken as Group A, the remainder being taken as Group B, a value of (O -E) as extreme as or more extreme than that actually observed would then be generated. The conditional argument considers the information in the data to be equivalent to that in a hypothetical set of independent 2 x 2 tables, one for each post-randomization day with margins equal to the margins of the 2 x 2 tables actually observed relating death on that day to group membership among those still at risk on that day. The conditional probability, P,ond, is then the probability that the value of (O -E) obtained by combining a set of such 2 x 2 tables in the usual way would be as extreme as or more extreme than the observed (O -E).
The permutational argument is usually applicable when two groups being compared have been separated by randomization, and is then preferable because Pperm will usually, although not always, be smaller than Pcond. The variance of (O -E) under the permutational argument is approximately V, and since there are usually many permutations that would lead to values of (O -E) very close to, buit not, equal to, the value of (O -E) actually obtained, Pperm is usually better estimated if a continuity correction is not used.
The conditional argument lacks a little of the efficiency of the permutational argument, but leads more naturally into Cox's (1972) methods, and into the study of treatment effects in particular time-periods. However, since it leads us, albeit slightly artificially, to regard E as fixed and 0 as an integer-valued random variable with variance exactly V, P0ond is usually better estimated if a continuity correction is used.
The conditional argument is always valid, but the permutational argument is sometimes not (e.g. if we compare survival among 2 groups of patients which have on average been followed up for different lengths of time). Nevertheless, when comparing the efficiency of the logrank test with that of alternative statistica tests for detecting differences between randomized groups, the efficiency of the permutational argument should be used. value of (O -E) in the ith subgroup, Asum = Eixi and the Vexact is EXijcij, where summation is over all groups from first to last inclusive and cij, the covariance of xi with xj, is given by Peto and Pike (1973) . A preferable test for trend, albeit one which is not accessible without statistical expertise, is then to take Asum2/Vexact (or, if a continuity correction is preferred, (IAsum -0-5)2/Vexact) as chi-square with 1 d.f. There is a strong connection between this recommended test for trend and the methods developed by Cox (1972) . These methods test for trend by attempting to relate the log hazard function linearly to the subgroup number by a parameter f and then testing g,B 0 by examining the log-likelihood function, L(fl). Since the quantity Asum equals Cox's L'(0), and in the absence of tied ranks the quantity Vexact equals Cox's L"(O) , it is therefore of full asymptotic efficiency in a reasonable class of models to base a test for trend on Asum.
